Alpha Tau Medical Ltd Cl A (DRTS)

2026-06-23T16:01:28.000Z - 11 days ago

Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT

Jun 23, 2026, 8:30 AM EDT - 11 days ago

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

2026-06-11T13:17:41.000Z - 23 days ago

Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial

Jun 11, 2026, 8:30 AM EDT - 23 days ago

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

2026-06-04T09:11:16.000Z - 4 weeks ago

Alpha Tau price target raised to $17 from $15 at Barclays

2026-06-03T14:53:02.000Z - 4 weeks ago

Alpha Tau, Tolmar announce strategic collaboration agreement

Jun 3, 2026, 8:30 AM EDT - 4 weeks ago

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

2026-06-01T13:43:39.000Z - 4 weeks ago

Alpha Tau reports positive survival data from pancreatic cancer study

Jun 1, 2026, 9:00 AM EDT - 4 weeks ago

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

May 28, 2026, 9:00 AM EDT - 5 weeks ago

Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference

2026-05-28T09:27:08.000Z - 5 weeks ago

Alpha Tau initiated with an Overweight at Barclays

2026-05-19T11:07:23.000Z - 6 weeks ago

Alpha Tau price target raised to $8 from $5 at Piper Sandler

2026-05-18T20:08:09.000Z - 6 weeks ago

Alpha Tau reports Q1 EPS (12c), consensus (12c)

May 18, 2026, 4:01 PM EDT - 6 weeks ago

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 4:00 PM EDT - 6 weeks ago

Alpha Tau Medical Earnings release: Q1 2026

May 18, 2026, 8:30 AM EDT - 6 weeks ago

Alpha Tau to Participate in May Investor Conferences

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Alpha Tau Medical Slides: Investor presentation

2026-05-12T15:35:38.000Z - 7 weeks ago

Alpha Tau price target raised to $14 from $12 at Ladenburg

2026-05-12T10:48:07.000Z - 7 weeks ago

Alpha Tau price target raised to $15 from $12 at H.C. Wainwright

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Transcript: Study result

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Press release: Study result

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Slides: Study result

2026-05-11T12:24:42.000Z - 7 weeks ago

Alpha Tau announces interim data from REGAIN trial

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

2026-05-08T15:18:00.000Z - 2 months ago

Alpha Tau completes enrollment in ReSTART trial

May 8, 2026, 9:10 AM EDT - 2 months ago

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

May 8, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

2026-05-07T18:29:44.000Z - 2 months ago

Alpha Tau treats first patient with Alpha DaRT in Italy

May 7, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

May 5, 2026, 9:14 AM EDT - 2 months ago

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

2026-05-04T14:13:20.000Z - 2 months ago

Alpha Tau presents updated results from two clinical trials of Alpha DaRT

May 4, 2026, 9:17 AM EDT - 2 months ago

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Alpha Tau Medical Registration statement: Registration filing

2026-04-28T10:16:48.000Z - 2 months ago

Alpha Tau files $300M mixed securities shelf

Apr 27, 2026, 9:01 AM EDT - 2 months ago

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

2026-04-23T13:33:45.000Z - 2 months ago

Alpha Tau gets FDA investigational device exemption supplement to IMPACT study

2026-04-23T13:26:53.000Z - 2 months ago

Alpha Tau treats first patient in ACAPELLA trial

Apr 23, 2026, 9:02 AM EDT - 2 months ago

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Apr 23, 2026, 9:01 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Mar 31, 2026, 9:15 AM EDT - 3 months ago

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Mar 18, 2026, 10:00 AM EDT - 3 months ago

Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference

Mar 16, 2026, 10:02 AM EDT - 3 months ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

2026-03-11T09:50:11.000Z - 4 months ago

Alpha Tau price target raised to $9 from $7 at Citi

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Alpha Tau Medical Slides: Investor presentation

Mar 9, 2026, 5:00 PM EDT - 4 months ago

Alpha Tau Medical Annual report: Q4 2025

Mar 9, 2026, 5:00 PM EDT - 4 months ago

Alpha Tau Medical Earnings release: Q4 2025

Mar 9, 2026, 4:02 PM EDT - 4 months ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Alpha Tau Medical Slides: Investor presentation

Feb 24, 2026, 8:51 PM EST - 4 months ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 9:00 AM EST - 4 months ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 3, 2026, 12:37 PM EST - 5 months ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Jan 29, 2026, 9:00 AM EST - 5 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 15, 2026, 4:00 PM EST - 6 months ago

Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 2:15 PM EST - 6 months ago

Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 5, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Dec 10, 2025, 11:30 AM EST - 7 months ago

Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference

Dec 9, 2025, 9:00 AM EST - 7 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Nov 21, 2025, 7:00 AM EST - 8 months ago

Alpha Tau Medical Slides: Investor presentation

Nov 20, 2025, 4:05 PM EST - 8 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 12:00 AM EST - 8 months ago

Alpha Tau Medical Earnings release: Q3 2025

Nov 11, 2025, 8:30 AM EST - 8 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 17, 2025, 10:04 AM EDT - 9 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Sep 30, 2025, 12:30 PM EDT - 9 months ago

Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 2, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Alpha Tau to Participate in Five September Investor Conferences

Aug 11, 2025, 4:02 PM EDT - 11 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 10, 2025, 6:00 PM EDT - 11 months ago

Alpha Tau Medical Earnings release: Q2 2025

Jul 25, 2025, 9:04 AM EDT - 1 year ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Alpha Tau Medical Registration statement: Registration Filing

May 19, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Mar 19, 2025, 11:30 AM EDT - 1 year ago

Alpha Tau Medical Transcript: Sidoti Small-Cap Virtual Conference

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q4 2024

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Annual report: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Transcript: R&D Day 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Slides: FY 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Alpha Tau Medical Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 18, 2024, 6:00 PM EST - 1 year ago

Alpha Tau Medical Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC